So here's a new way to think about your weight-loss journey: as a monthly subscription service. Eli Lilly and Co. (LLY) announced on Wednesday that its new obesity pill, Foundayo (orforglipron), is now available for adults who are overweight or have obesity with related health issues. It's a once-daily pill you can take without worrying about food or water restrictions, which is basically the pharmaceutical version of "user-friendly."
The U.S. Food and Drug Administration gave it the green light last week under a fast-track review. The idea is you take it while also, you know, trying to eat a bit less and move a bit more. In trials, it helped people lose an average of 27 pounds at the highest dose.
"Foundayo delivers meaningful weight loss... and we made the path from prescription to doorstep as simple as possible," said Ilya Yuffa, an executive vice president at Lilly.
And that path is getting wider fast. You can get it now through Lilly's own digital platform, LillyDirect, and through telehealth providers. Starting today, it's also rolling out to retail pharmacies across the U.S.
The Price Tag and the Fine Print
Alright, let's talk money. If you're paying out of pocket, the lowest dose starts at $149 a month. That's the headline number. But if you have commercial insurance that covers Foundayo, you might get it for as little as $25 a month with a savings card. And for eligible folks on Medicare Part D, there's a potential $50-a-month price starting July 1, 2026.
It's a competitive move in a market that's getting seriously crowded. Lilly isn't just launching a pill; it's launching an inventory. The company revealed in February that it has stockpiled $1.5 billion worth of orforglipron. That's up from about $550 million last year. They've said they expect to have enough supply to roll this thing out in multiple countries at nearly the same time. They're not just dipping a toe in the water; they're building a bridge.
The Other Guy in the Ring
This all happens while the other heavyweight in the weight-loss drug arena, Novo Nordisk A/S (NVO), is making its own power moves. Back in February, Novo said it plans to cut the list prices of its GLP-1 drugs—think Wegovy, Ozempic, Rybelsus—by up to 50% in the U.S. starting in 2027. That would bring a new list price down to around $675 a month from current prices that can range from over $1,000 to $1,350.
So you've got Lilly coming in with a new, conveniently priced oral option, and Novo preparing to slash prices on its established injectables in a couple of years. The obesity drug war is officially a price war, too.
As for Lilly's stock? Shares were up a modest 0.23% at $955.47 when this was published, according to market data.
